- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Bromfenac sodium receives award for best new branded drug introduction of 2005
ISTA Pharmaceuticals Inc. announced that the company?s launch of bromfenac sodium ophthalmic solution 0.09% (Xibrom) received the 2005 Healthcare Distribution Management Association (HDMA) Award for the Best New Branded Pharmaceutical Product Introduction and/or Product Promotion.
Chicago-ISTA Pharmaceuticals Inc. announced that the company’s launch of bromfenac sodium ophthalmic solution 0.09% (Xibrom) received the 2005 Healthcare Distribution Management Association (HDMA) Award for the Best New Branded Pharmaceutical Product Introduction and/or Product Promotion.
The HDMA announced its Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) recently during the organization’s Annual Leadership Forum.
Bromfenac sodium is ISTA Pharmaceutical’s topical ophthalmic, non-steroidal, anti-inflammatory compound for the treatment of ocular inflammation following cataract surgery. The drug was approved by the FDA in March 2005 and was launched in the second quarter of 2005.
More information is available at ISTA Pharmaceuticals’ Booth 3375.
